Cancer Diagnostic Collaboration and Licensing Deals 2016-2024
Cancer Diagnostic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024
Cancer Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer diagnostic deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of cancer diagnostic deals from 2016 to 2024.
The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 846 cancer diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of cancer diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in cancer diagnostic dealmaking since 2016.
Chapter 3 provides an overview of the leading cancer diagnostic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Cancer Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2016
• Browse cancer diagnostic collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Report scope
Cancer Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.
Cancer Diagnostic Collaboration and Licensing Deals includes:
• Trends in cancer diagnostic dealmaking in the biopharma industry
• Directory of cancer diagnostic deal records covering pharmaceutical and biotechnology
• The leading cancer diagnostic deals by value
• Most active cancer diagnostic licensing dealmakers
Cancer Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Cancer Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2016
• Browse cancer diagnostic collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in cancer diagnostic dealmaking
2.1. Introduction
2.2. Cancer diagnostic deals over the years
2.3. Most active cancer diagnostic dealmakers
2.4. Cancer diagnostic deals by deal type
2.5. Cancer diagnostic deals by therapy area
2.6. Cancer diagnostic deals by industry sector
2.7. Deal terms for cancer diagnostic deals
2.7.1 Cancer diagnostic deals headline values
2.7.2 Cancer diagnostic deal upfront payments
2.7.3 Cancer diagnostic deal milestone payments
2.7.4 Cancer diagnostic royalty rates
Chapter 3 – Leading cancer diagnostic deals
3.1. Introduction
3.2. Top cancer diagnostic deals by value
Chapter 4 – Most active cancer diagnostic dealmakers
4.1. Introduction
4.2. Most active cancer diagnostic dealmakers
4.3. Most active cancer diagnostic deals company profiles
Chapter 5 – Cancer diagnostic contracts dealmaking directory
5.1. Introduction
5.2. Cancer diagnostic contracts dealmaking directory
Chapter 6 – Cancer diagnostic dealmaking by technology type
Deal directory
Deal directory – Cancer diagnostic deals by company A-Z
Deal directory – Cancer diagnostic deals by deal type
Deal directory – Cancer diagnostic deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Cancer diagnostic deals since 2016
Figure 2: Active cancer diagnostic dealmaking activity – 2016 - 2024
Figure 3: Cancer diagnostic deals by deal type since 2016
Figure 4: Cancer diagnostic deals by therapy area since 2016
Figure 5: Cancer diagnostic deals by industry sector since 2016
Figure 6: Cancer diagnostic deals with a headline value
Figure 7: Cancer diagnostic deals with an upfront value
Figure 8: Cancer diagnostic deals with a milestone value
Figure 9: Cancer diagnostic deals with a royalty rate value
Figure 10: Top cancer diagnostic deals by value since 2016
Figure 11: Most active cancer diagnostic dealmakers 2016 - 2024
Figure 12: Cancer diagnostic deals by technology type since 2016
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $9,995: company (unencrypted PDF)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.